Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX05 vs Herceptin in HER2+ Early Breast Cancer
NCT03556358Phase 3Completed
- Sponsor
- Tanvex BioPharma, Inc.
- Start
- Jun 2018
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of TrastuRel in breast cancer, sponsored by Tanvex BioPharma, Inc.. Started Jun 2018; status: completed.
02
Drugs
TrastuRel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03556358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556358.